Antibody-dependent cellular phagocytosis in cancer immunotherapy: research and perspectives
Journal of Translational Medicine · 19.03.2026 · 24 (1)
DOI: 10.1186/s12967-026-08020-5 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Translational Medicine, online erschienen am 19.03.2026. Verfasst von Qihong Gu und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Public Health, Nantong University, Nantong, China. Hauptthemen laut MEDLINE: Immunotherapy, Neoplasms, Phagocytosis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 111 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Program of Youth Project of the Natural Science Foundation of Nantong, the Program of Youth Program of Jiangsu Provincial Natural Science Foundation.
Abstract (Originalsprache)
Background
Cancer immunotherapy has revolutionized the clinical management of cancer due to its promising survival benefits. Although FDA-approved cancer immunotherapy primarily leverages adaptive immunity for therapeutic efficacy, the critical role of innate immunity in tumor surveillance and eradication has been increasingly recognized. Recently, with the deepening of research in this field, macrophages have emerged as key effectors of the innate anti-tumor response, with antibody-dependent cellular phagocytosis (ADCP) becoming one of the primary mechanisms involved in cancer immunotherapy. As such, exploring ADCP-inducing monoclonal antibodies (mAbs) as forefront therapeutic regimens for patients with cancer is therefore highly sought after. Main body Here, we broadly summarize recent translational advances in harnessing macrophage phagocytosis as a pivotal therapeutic approach in cancer immunotherapy, especially addressing how intravital imaging sheds light on ADCP in a real-time manner. Moreover, various challenges for targeting phagocytosis, strategies to enhance ADCP, and factors limiting its efficiency have also been summarized. We also investigated the potential of chimeric antigen receptor (CAR) macrophages as a next-generation therapeutic modality that bridges the innate and adaptive immune systems to induce robust anti-tumor immune responses.
Conclusions
The insights presented in this review will set the scene for future investigations of possible alternative approaches that consider the antibody-dependent cellular phagocytosis for improved cancer immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Public Health, Nantong University, Nantong, China.
- The Affiliated Chuzhou Hospital of Anhui Medical University, The First People's Hospital of Chuzhou, Chuzhou, China.
- Medical School of Nantong University, Nantong, China.
- Department of Health Technology and Informatics, The Hong Kong Polytechnic University, Kowloon, Hong Kong SAR, P.R. China.
- Suzhou Key Laboratory of Medical Biotechnology, Suzhou Vocational Health College, Suzhou, China. liusongbai@126.com.
- School of Public Health, Nantong University, Nantong, China. chuminjie@ntu.edu.cn.
Förderung
- the Program of Youth Project of the Natural Science Foundation of Nantong
- the Program of Youth Program of Jiangsu Provincial Natural Science Foundation
Zitieren
APA
Gu, Q., Li, S., Hou, S., Liu, J., Zhang, X., Xi, Y., Chen, H., Liu, S., Chu, M., & Yang, M. (2026). Antibody-dependent cellular phagocytosis in cancer immunotherapy: research and perspectives. Journal of Translational Medicine, 24(1). https://doi.org/10.1186/s12967-026-08020-5
Vancouver
Gu Q, Li S, Hou S, Liu J, Zhang X, Xi Y, et al. Antibody-dependent cellular phagocytosis in cancer immunotherapy: research and perspectives. Journal of Translational Medicine. 2026;24(1). doi:10.1186/s12967-026-08020-5
BibTeX
@article{Gu2026,
author = {Gu, Qihong and Li, Siqi and Hou, Shiqiang and Liu, Jiahao and Zhang, Xinyang and Xi, Yan and Chen, Hongzhao and Liu, Songbai and Chu, Minjie and Yang, Minfeng},
title = {Antibody-dependent cellular phagocytosis in cancer immunotherapy: research and perspectives},
journal = {Journal of Translational Medicine},
year = {2026},
volume = {24},
number = {1},
doi = {10.1186/s12967-026-08020-5}
}
EUVIMED